Le Lézard1h
Ellipses In-Licences First in Class Novel Immuno-Oncology Agent With Potential as a Next Generation Checkpoint Inhibitor
Ellipses Pharma Limited ("Ellipses"), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced today it is ...
Miamisburg-based Riverain Technologies receives FDA clearance for AI-powered imaging software
A Dayton-area medical technology firm has recently had its AI-driven image processing and analysis technology cleared by the ...
BioRay's ROR1-Targeting Dual-Epitope ADC Drug BR111 Receives Formal Clinical Trial Approval from NMPA
On December 19, 2024, BioRay Pharmaceutical Co., Ltd. ('BioRay') announced that the National Medical Products Administration (NMPA) has accepted the clinical trial application for its self-developed C ...
Zymeworks: Its Post-Approval Future
Shares of solid tumor concern Zymeworks Inc. have barely budged since the company obtained its first approval. Click here to read why ZYME stock is a Hold.
BioPharma Dive21h
The role of diagnostics in advancing antibody-drug conjugates
From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...
ophthalmologyadvisor22h
FDA Approves Wearable Infusion Device for Advanced Parkinson Disease
The US Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in ...
FiercePharma1d
AbbVie scores FDA nod for Pfizer-partnered antibiotic Emblaveo
Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...